Encouraging ?

In Phase II, we demonstrated that a single injection of our highest dose, which is a dose currently being evaluated in a Phase III trial, prevented any hospitalizations or deaths over a three-year period. In contrast, control patients had at least a 30% incidence of a heart-failure-related major adverse cardiac event, and patients who were at the more extreme ends who were matched for severity showed a much higher event rate. The fact that a single injection of this highest dose prevented our patients from any hospitalizations or deaths over three years was encouraging.........Encouraging !! Come on Silviu Its bloody Magnificant .......................................................................................................................................................................................... The FDA has seen CHF early interim data on the phase 111 and if its similar to the phase 11 data they will be constructing a plan if its not already made.......Imagine a north wing and south wing of a hospital one with CHF control patients dying ,the other with CHF patients going home .. V